A Double Blind,Placebo-Controlled Trial of Ipriflavone for Prevention of Postmenopausal Spinal Bone Loss |
| |
Authors: | D. Agnusdei G. Crepaldi G. Isaia G. Mazzuoli S. Ortolani M. Passeri L. Bufalino C. Gennari |
| |
Affiliation: | (1) Institute of Internal Medicine and Medical Pathology, University of Siena, Nuovo Policlinico, Viale Bracci I-53100-Siena, Italy, IT;(2) Institute of Internal Medicine, University of Padua, Italy, IT;(3) Institute of Internal Medicine, University of Turin, Italy, IT;(4) Institute of Internal Medicine, University of Rome, Italy, IT;(5) Institute of Internal Medicine, University of Milan, Italy, IT;(6) Institute of Internal Medicine, University of Parma, Italy, IT;(7) Medical Department, Chiesi Farmaceutici S.p.A., Parma, Italy, IT |
| |
Abstract: | One hundred ninety-eight postmenopausal women (aged 50–65 years) with vertebral bone density (VBD) 1 SD below the mean value for normal, age-matched, postmenopausal subjects were enrolled in six Italian centers and 134 completed 2 years of treatment. All subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d.) or a matching placebo, according to a double-blind, parallel group design. All patients also received an oral daily calcium supplement of 1 g as calcium carbonate. VBD and markers of bone turnover were measured at baseline, and every 6 months. A complete routine analysis of liver and kidney functions along with hematological parameters were measured before and at the end of treatment period. The valid completers analysis showed a significant increase of VBD in ipriflavone-treated women with average percent changes of +1.4 after 1 year, and +1% at the end of treatment period (P < 0.05). The placebo group presented a significant decrease of VBD after 2 years of treatment (P < 0.05). The difference between treatments was significant (P < 0.01). The intention to treat analysis confirmed the significant decrease of VBD in the placebo group, with no changes in ipriflavone-treated women. Skeletal ALP significantly decreased in ipriflavone-treated women (P < 0.05). Serum BGP and urine HOP/Cr showed a significant decrease only in ipriflavone-treated women, suggesting an inhibitory effect on bone turnover rate. Adverse reactions, mainly gastrointestinal, occurred to a similar extent in the two treatment groups. The evaluation of patients' compliance, assessed by residual tablets count, revealed a drug intake of more than 80% after 2 years in 92.5% and 92.8% of patients treated with ipriflavone or placebo, respectively. This study demonstrates that ipriflavone can prevent bone loss in postmenopausal women with low bone mass. Received: 1 April 1996 / Accepted: 5 March 1997 |
| |
Keywords: | : Bone loss — Bone turnover — Ipriflavone — Vertebral bone mass. |
本文献已被 SpringerLink 等数据库收录! |
|